We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Accelerated Genomics Cloud Promotion Designed to Enhance Research Workflows

By LabMedica International staff writers
Posted on 13 May 2013
Convey Computer (Richardson, TX, USA) reported that Nimbix (Dallas, TX, USA), a developer of accelerated high-performance cloud computing systems, has partnered with Convey to expand its Convey hybrid-core (HC) infrastructure, as part of The Accelerated Genomics Cloud (TAGC) promotion, which provides free runtime for qualified applicants. More...


The Convey HC-2ex platform will be used in research projects for customers who take advantage of the promotion. A total of USD 25,000 worth of cloud processing time will be awarded to genomics researchers to increase their bioinformatics analysis. Top award recipients will each receive USD 1,000 of runtime, which is enough to map up to 3 Tbases of reads, providing the ability to analyze, for example, 12 human genomes at considerable coverage. Remaining qualified applicants will receive USD 500 of runtime.

TAGC promotion began April 30, 2013, and the first awards will be granted as soon as the application review process allows. The promotion will end July 1, 2013, or once all funding has been awarded. Therefore, interested participants may register online (please see Related Links below).

Runtime, for those applicants selected, will include a range of Nimbix resources, which includes a combination of Convey and conventional large memory systems configured to provide the best performance across a range of applications and workflows. These may include reference mapping, de novo assembly, functional annotation, variant analysis, and RNA expression profiling. Participants, for example, will have access to the full Convey Bioinformatics Suite, as well as third-party applications optimized for the hybrid-core architecture.

“Genomics is perhaps the clearest example where progress is accelerated by access to the right HPC [high-performance computing] resource and stymied when those resources are missing,” stated Dr. George Vacek, director of Convey Computer’s life sciences business unit.

“Heterogeneous computing has become a necessity in life sciences, where the data production from next-generation sequencing instruments is increasing much more quickly than traditional computing resources can handle.”

The combination of heterogeneous computing and cloud computing is a suitable approach for high performance computing demands in life sciences. Budget constraints are limiting access to vital compute resources at the very time when the incredible growth in life sciences data makes access increasingly advantageous. “HPC-oriented clouds supporting the latest heterogeneous architectures can provide even small research groups with affordable access to diverse computer resources,” said Steve Hebert, cofounder of Nimbix. “Our goal through this promotion is to give genomics researchers access to world-class HPC resources and to show them that heterogeneous cloud computing is extremely powerful, yet simple and affordable.”

Nimbix installed their first Convey system in 2011 when the two companies collaborated to offer Convey’s novel hybrid-core architecture and bioinformatics personalities as a cloud-based HPC solution. Since then, users of the Nimbix Accelerated Compute Cloud have achieved greater than 50x speed-up of sequence searches using Convey’s hybrid-core system. Users have also seen impressive acceleration, inclusive of data transfer times, for mapping and de novo assembly—both in terms of improving runtimes and increasing throughput.

Convey’s hybrid-core architecture pairs classic Intel x86 microprocessors with a coprocessor comprised of field-programmable gate arrays (FPGAs). Specific algorithms, DNA sequence assembly, for example, are optimized and converted into code that is loadable onto the FPGAs at runtime. The Convey architecture also features a highly parallel memory subsystem to additionally increase performance. Convey’s approach provides very fast access to random access memory, which is helpful for the hashing functions so widely used in bioinformatics.

Convey Computer’s world’s first hybrid-core computer—a system that fuses the low cost and simple programming model of a commodity system with the performance of a personalized hardware architecture.

Nimbix is a provider of cloud-based, HPC infrastructure and applications. Nimbix offers HPC applications as a service through the Nimbix Accelerated Compute Cloud, dramatically speeding up data processing for life sciences, oil and gas, and Rendering applications. Nimbix operates unique high performance hybrid systems and accelerated servers in its Dallas, TX, USA, datacenter.

Related Links:

Convey Computer
Nimbix
TAGC Promotion



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.